{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T16:13:52Z","timestamp":1789661632480,"version":"4.0.1"},"reference-count":35,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T00:00:00Z","timestamp":1675728000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["alz-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Alzheimer's &amp;amp; Dementia"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Alzheimer's disease (AD) clinical trials are designed and powered to detect the impact of a therapeutic intervention, and there has been considerable discussion on what constitutes a clinically meaningful change in those receiving treatment versus placebo. The pathology of AD is complex, beginning many years before clinical symptoms are detectable, with multiple potential opportunities for therapeutic engagement. Introducing treatment strategies early in the disease and assessing meaningful change over the course of an 18\u2010month clinical trial are critical to understanding the value to an effective intervention. With new clinical trial data expected soon on emerging therapeutics from several AD studies, the Alzheimer's Association convened a work group of experts to discuss key considerations for interpreting data from cognitive and functional measures and what is considered a clinically meaningful benefit or meaningful slowing of this fatal disease. Our expectations of outcomes from therapeutic interventions in AD may need to be modified.<\/jats:p>","DOI":"10.1002\/alz.12959","type":"journal-article","created":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T07:09:53Z","timestamp":1675753793000},"page":"2730-2736","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":88,"title":["Expectations and clinical meaningfulness of randomized controlled trials"],"prefix":"10.1002","volume":"19","author":[{"given":"Ronald C.","family":"Petersen","sequence":"first","affiliation":[{"name":"Department of Neurology Mayo Clinic  Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul S.","family":"Aisen","sequence":"additional","affiliation":[{"name":"USC Alzheimer's Therapeutic Research Institute  San Diego California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Scott","family":"Andrews","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Atri","sequence":"additional","affiliation":[{"name":"Banner Sun Health Research Institute Banner Health  Sun City Arizona USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandy R.","family":"Matthews","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorene M.","family":"Rentz","sequence":"additional","affiliation":[{"name":"Center for Alzheimer Research and Treatment Brigham and Women's Hospital and Department of Neurology Massachusetts General Hospital Harvard Medical School  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric R.","family":"Siemers","sequence":"additional","affiliation":[{"name":"Siemers Integration LLC  Zionsville Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Weber","sequence":"additional","affiliation":[{"name":"Alzheimer's Association  Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria C.","family":"Carrillo","sequence":"additional","affiliation":[{"name":"Alzheimer's Association  Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,2,7]]},"reference":[{"key":"e_1_2_7_2_1","unstructured":"Food and Drug Administration.Peripheral and central nervous system drugs advisory committee meeting July 7 1989.Rockville MD:Department of Health and Human Services Public Heath Service;1989. p.227."},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01382-x"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00361-6"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2018.02.018"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0755-1"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-020-00923-z"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awab163"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23746-0"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2022.30"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2100708"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010021\u201001369\u20108"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13195\u2010021\u201000813\u20108"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13195\u2010020\u201000659\u20106"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40271\u2010022\u201000576\u2010w"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trci.2019.06.005"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2022.102"},{"key":"e_1_2_7_18_1","unstructured":"U.S. Food and Drug Administration Discussion Document for Patient\u2010Focused Drug Development (PFDD) Public Workshop on Guidance 4: Incorporating Clinical Outcome Assessments into Endpoints for Regulatory Decision\u2010Making December 6 2019.https:\/\/www.fda.gov\/drugs\/development\u2010approval\u2010process\u2010drugs\/public\u2010workshop\u2010patient\u2010focused\u2010drug\u2010development\u2010guidance\u20104\u2010incorporating\u2010clinical\u2010outcome"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2022.103"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.140.6.566"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2015.82"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp\u20102015\u2010312383"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.43.11.2412-a"},{"issue":"9","key":"e_1_2_7_24_1","doi-asserted-by":"crossref","first-page":"550","DOI":"10.14283\/jpad.2022.22","article-title":"What matters to patients with Alzheimer's disease and their care partners? Implications for understanding the value of future interventions","volume":"3","author":"Jessen F","year":"2022","journal-title":"J Prev Alz Dis"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/s41687-019-0100-y"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2019.09.074"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.9581"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007831"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13195\u2010022\u201000984\u2010y"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0119632"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12009"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00401\u2010011\u20100826\u2010y"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00401\u2010017\u20101717\u20107"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000006088"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2016.02.007"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2019.12"}],"container-title":["Alzheimer's &amp; Dementia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/alz.12959","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/alz.12959","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/alz.12959","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:54:46Z","timestamp":1759971286000},"score":1,"resource":{"primary":{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/10.1002\/alz.12959"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,7]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["10.1002\/alz.12959"],"URL":"https:\/\/doi.org\/10.1002\/alz.12959","archive":["Portico"],"relation":{},"ISSN":["1552-5260","1552-5279"],"issn-type":[{"value":"1552-5260","type":"print"},{"value":"1552-5279","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,7]]},"assertion":[{"value":"2022-10-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}